Congenital malformations now represent the largest single cause of mortality in the infant of the diabetic mother. The mechanism by which diabetes exerts its teratogenic effects is not known. This study evaluated whether arachidonic acid might be involved, a possibility raised by the role of arachidonic acid in palatal elevation and fusion, processes analogous to neural tube folding and fusion. This hypothesis was tested in two animal models of diabetic embryopathy, the in vivo pregnant diabetic rat and the in vitro hyperglycemic mouse embryo culture. The subcutaneous injection of arachidonic acid (200-400 mg/kg per day) into pregnant diabetic rats during the period of organ differentiation (days 6-12) did not alter the maternal glucose concentration, the maternal weight gain, or the weight of the embryos. However, the incidence of neural tube fusion defects was reduced from 11% to 3.8% (P < 0.005), the frequency of deft palate was reduced from 11% to 4% (P < 0.005), and the incidence of micrognathia was reduced from 7% to 0.8% (P < 0.001). The addition of arachidonic acid to B10.A mouse embryos in culture also resulted in a reversal of hyperglycemiainduced teratogenesis. The teratogenic effect of D-glucose (8 mg/ml) in the medium resulted in normal neural tube fusion in only 32% of the embryos (P < 0.006 when compared to controls). Arachidonic acid supplementation (1 or 10 jug/ml) produced a rate of neural tube fusion (67%) that was not significantly different from that observed in controls. The evidence presented indicates that arachidonic acid supplementation exerts a significant protective effect against the teratogenic action of hyperglycemia in both in vivo (rat) and in vitro (mouse) animal models. These data therefore suggest that the mechanism mediating the teratogenic effect of an increased glucose concentration involves a functional deficiency of arachidonic acid at a critical stage of organogenesis.Although major advances have been made over the past 20 years in the prognosis of the newborn infant of the diabetic mother, no appreciable improvements have been noted in the rates of malformations seen in these infants (1, 2). Malformations have now become the leading cause of death in infants of diabetic mothers (3). Although the lesion most specific for human maternal diabetes is the caudal regression syndrome (4), spina bifida, hydrocephalus, anencephaly, and other central nervous system defects also occur at a high rate (5). This had led to studies of diabetic embryopathy focused on animal models of failure of neural tube folding and fusion. These defects can be produced by exposing either rat or mouse embryos to high concentrations of glucose in vitro, thus demonstrating that increased glucose levels alone are sufficient to produce malformations (6, 7). However, the mechanism linking hyperglycemia with malformations remains unknown. In this paper, we present evidence that exogenous arachidonic acid exerts a highly significant protective effect against the teratogenic action of hyperglycemia i...

In order to define further the mechanisms responsible for tooth amelogenin heterogeneity, seven bovine amelogenin cDNAs were sequenced. On the basis of these sequences, five of the cDNAs could be grouped into one class which differed appreciably in sequence from the second group of two cDNAs. Two overlapping bovine genomic clones were then isolated and shown by sequencing to contain six exons encoding the entire consensus sequence of the class I cDNA. Southern blot analysis of DNA from male and female animals using class I or class II specific oligonucleotide probes suggested that the class I gene sequence was located on the X chromosome while the class II sequence was located on the Y chromosome. Therefore, these results also suggest that the genes on the X and Y chromosomes are both transcribed. Furthermore, the results are consistent with alternative splicing of the class I primary transcript as a potential mechanism for generating amelogenin heterogeneity.

Summary. Reptilase®‐R, a purified thrombin‐like snake‐venom enzyme from Bothrops atrox, has been tested for its usefulness as a substitute for thrombin in two coagulation assay systems. Reptilase was found to be more stable than thrombin and not to be inhibited by heparin and hirudin. Performance of the Reptilase time allows the rapid exclusion of heparin contamination in plasma samples with prolonged thrombin times. In the presence of fibrinogen/fibrin split products, the Reptilase time is less prolonged than the thrombin time, whereas in patients with prolonged thrombin times because of congenital dysfibrinogenaemia the inverse is found. Thus, performance of both Reptilase time and thrombin time allows the rapid identification of three major causes for a prolongation of the thrombin time. In patients on heparin therapy because of a defibrination syndrome, the Reptilase time may replace the thrombin time as a guide for the degree of coagulation inhibition by FDP, although our results show that it is somewhat less sensitive. Reptilase can also be substituted for thrombin in the rapid chronometric fibrinogen assay. Unfortunately the advantages of reagent stability and insensitivity to heparin are balanced by a lesser reproducibility, especially in the presence of FDP.

No abstract

The indirect method of immunofluorescence was used to demonstrate the presence of amelogenins in the enameloid of teeth and dermal denticles of Chondrichthyes; in the enameloid of Teleostei and Amphibia; and in the enamel of Reptilia. Nonmammalian amelogenins are formed in the ectodermal cells of tooth organs and chemically are so similar to mammalian amelogenins that they interact with antiserum prepared from bovine enamel matrix.